Q&A

EHA Library, Faculty / Presenters, 312325

Questions and Discussion

EHA Library, Nicola Gökbuget, 312326

Q&A

EHA Library, Faculty / Presenters, 312327

Asparaginase pharmacokinetics and pharmacodynamics

EHA Library, M Relling, 312328

Efficacy, tolerability and management strategies in the GMALL trials

EHA Library, Nicola Gökbuget, 312329

Toxicities in adult versus pediatric ALL patients and consequences for management

EHA Library, K Schmiegelow, 312330

COVID-19 and SCD: The experts in conversation

EHA Library, Ifeyinwa Osunkwo, 312331

Welcome and Introduction

EHA Library, Ifeyinwa Osunkwo, 312332

Effective management of VOCs: Overcoming barriers and finding solutions

EHA Library, Ifeyinwa Osunkwo, 312333

Living with SCD: Understanding the consequences

EHA Library, R Colombatti, 312334

Treatment of the older patient with AML

EHA Library, Courtney DiNardo, 313469

Eosinophilia

EHA Library, Andreas Reiter, 313466

Classification and clinical approach to atypical microcytic anemias

EHA Library, Patricia Aguilar Martinez, 313462

Basis of iron regulation for erythropoiesis

EHA Library, Laura SILVESTRI, 313461

Natural Killer Cell-Mediated Immunosurveillance of leukemia

EHA Library, Yenan Bryceson, 313459

Immunotherapy and other novel immunological therapies

EHA Library, Daniel Olive, 313458

Management of MM patients with high-risk disease

EHA Library, Jesús San Miguel, 313457

Testicular lymphoma

EHA Library, Annalisa Chiappella, 313453

Primary mediastinal lymphoma

EHA Library, Maurizio Martelli, 313452

New drugs and BMT: How to choose

EHA Library, Maria Domenica Cappellini, 313450

Genetic heterogeneity of congenital neutropenias

EHA Library, Karl Welte, 313444

Building blocks to optimize CLL treatment

EHA Library, Thorsten Zenz, 313440

Vulnerabilities of indolent lymphomas: The tumor and the microenvironment

EHA Library, Leticia Quintanilla de Fend, 313437

Management of post allogeneic HCT auto/alloimmune cytopenia

EHA Library, Andreas Holbro, 313436

Sickle cell disease as a chronic problem

EHA Library, Marianne de Montalambert, 313485

New insights in the pathogenesis of autoimmune hemolytic diseases

EHA Library, Wilma Barcellini, 313434

Novel agents for phase 3 trials

EHA Library, Michel Zwaan, 313433

Advances in risk stratification in pediatric acute lymphoblastic leukemia

EHA Library, Anthony Moorman, 313432

ALL subtypes

EHA Library, Ilaria Iacobucci, 313431

Red cell transfusions: Current best practice and how to further optimize?

EHA Library, Marlijn Hoeks, 313430

Epidemiology of Hbpathies in Europe

EHA Library, Fred Piel, 313429

Real life CAR T treatment

EHA Library, Catherine Thieblemont, 313427

Novel treatment options

EHA Library, Subarna Chakravorty, 313426

Iron overload, monitoring and management

EHA Library, Ali Taher, 313425

CAR T cells

EHA Library, Paula Rodríguez-Otero, 313424

T-cell engaging antibodies for hematological diseases from approved therapies to new indications

EHA Library, Hermann Einsele, 313423

Improving efficacy and persistence of CAR-T cell

EHA Library, Christian Chabannon, 313422

Hydroxyurea: Fertility a still open question in adulthood

EHA Library, David Rees, 313421

Inherited platelet disorders and mutations in hematopoietic transcription factors

EHA Library, A. Koneti Rao, 313473

Immune thrombocytopenia (ITP): New insights on pathophysiology

EHA Library, John Semple, 313474

TTP vs HUS - Novel insights

EHA Library, Marie Scully, 313475

Biological basis of transformation

EHA Library, Ulf Klein, 313476

Current treatment options for transformed disease

EHA Library, Silvia Montoto, 313477

Potentially druggable targets in transformed disease

EHA Library, Davide Rossi, 313478

Update on oral contraception and VTE

EHA Library, Marc Blondon, 313480

Niche contributions to bone marrow failure and clonal evolution in MDS

EHA Library, Marc Raaijmakers, 313482

The molecular basis of p53 mutations in MDS

EHA Library, Benjamin Ebert, 313483

Drug induced immune hemolytic disease: Diagnostic challenges

EHA Library, Quentin A Hill, 313435

METFORMIN AND STATINS DO NOT LOWER MYELOFIBROSIS INCIDENS, OVERALL SURVIVAL OR RISK OF LEUKEMIC TRANFORMATION: A DANISH NATIONWIDE COHORT STUDY

EHA Library, Daniel Kristensen, 293583

LONG-TERM SAFETY OF FEDRATINIB IN PATIENTS WITH INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF)

EHA Library, Animesh Pardanani, 293585

24-H URINE: IS IT REALLY NECESSARY FOR MULTIPLE MYELOMA FOLLOW-UP?

EHA Library, Joao Pedro Barreto, 293531

TELOMERASE ACTIVITY, TELOMERE LENGTH AND HTERT EXPRESSION CORRELATE WITH CLINICAL OUTCOMES IN HIGHER-RISK MYELOFIBROSIS (MF) RELAPSED/REFRACTORY (R/R) TO JANUS KINASE INHIBITOR TREATED WITH IMETELSTAT

EHA Library, John Mascarenhas, 293587

PHENOTYPIC DIFFERENCES AND PROGNOSTIC IMPACT OF SIGNALING MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Evandro Bezerra, 293582

MYELOPROLIFERATIVE NEOPLASMS-UNCLASSIFIABLE: CLINICOPATHOLOGICAL CHARACTERISATION AND OUTCOME ANALYSIS

EHA Library, Paul Deschamps, 293581

CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS MONOTHERAPY IN ADVANCED MYELOFIBROSIS PATIENTS REFRACTORY/INTOLERANT TO JAK INHIBITOR: UPDATE FROM PHASE 2 MANIFEST STUDY

EHA Library, Moshe Talpaz, 293580

CHRONIC NEUTROPHILIC LEUKEMIA AND ATYPICAL CHRONIC MYELOID LEUKEMIA ARE HIGLY OVERLAPPING DISORDERS. RESULTS FROM AN INTERNATIONAL BRITISH-SPANISH STUDY

EHA Library, Gonzalo Carreno Gomez-Tarragona, 293579

INTERIM ANALYSIS OF A PHASE II TRIAL (HOVON-134) IN MYELOFIBROSIS PATIENTS (PRIMARY, POST-ET OR POST PV-MF) TREATED WITH THE JAK2 INHIBITOR PACRITINIB BEFORE RIC ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Peter te Boekhorst, 293578

CLINICIAL, MORPHOLOGICAL AND GENETIC EVIDENCE FOR TWO INDEPENDENT DISEASES IN PATIENTS CONCURRENTLY POSITIVE FOR JAK2 V617F AND KIT D816V

EHA Library, Juliana Schwaab, 293577

CO-MUTATIONS AND NON-CANONICAL DRIVER MUTATIONS IDENTIFIED BY NEXT GENERATION SEQUENCING IN MYELOPROLIFERATIVE NEOPLASMS REVEAL SIGNIFICANT OPPORTUNITIES FOR IMPROVED DIAGNOSTIC PRACTICE

EHA Library, Ella Thompson, 293576

ROPEGINTERFERON ALPHA-2B IS EFFICACIOUS AND REDUCES VARIANT TET2 ALLELE BURDEN IN PATIENTS WITH POLYCYTHAEMIA VERA AND TET2 MUTATION: GENETIC ANALYSIS OF PHASE III PROUD-PV/CONTINUATION-PV STUDIES

EHA Library, Robert Kralovics, 293574

CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR TREATMENT NAÏVE MYELOFIBROSIS PATIENTS: UPDATE FROM MANIFEST PHASE 2 STUDY

EHA Library, John Mascarenhas, 293573

CPI-0610, BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS 'ADD-ON' TO RUXOLITINIB (RUX), IN ADVANCED MYELOFIBROSIS PATIENTS WITH SUBOPTIMAL RESPONSE: UPDATE OF MANIFEST PHASE 2 STUDY

EHA Library, Srdan Verstovsek, 293572

RESULTS FROM PIONEER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF AVAPRITINIB IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS

EHA Library, Cem Akin, 293571

NAVITOCLAX IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS: A PHASE 2 STUDY

EHA Library, Claire Harrison, 293570

A PHASE 2 STUDY OF BOMEDEMSTAT (IMG-7289), A LYSINE-SPECIFIC DEMETHYLASE-! (LSD!) INHIBITOR, FOR THE TREATMENT OF LATER-STAGE MYELOFIBROSIS (MF)

EHA Library, Kristen Pettit, 293569

AVAPRITINIB INDUCES RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), REGARDLESS OF PRIOR MIDOSTAURIN THERAPY

EHA Library, Jason Gotlib, 293568

ROLE OF TRAINED IMMUNITY AND IMMUNOMETABOLISM IN THE PATHOGENESIS OF ERDHEIM-CHESTER DISEASE

EHA Library, Giulio Cavalli, 293567

CLINICAL SIGNIFICANCE OF MPL MUTATIONS IN ESSENTIAL THROMBOCYTEMIA PATIENTS: RISK ASSESMENT OF MYELOFIBROTIC TRANSFORMATION.

EHA Library, Rocío García-Serra, 293566

CLINICAL AND BIOLOGICAL FEATURES DISTINGUISH MYELOID DISEASES FROM MYELOID DISORDERS ASSOCIATED WITH AUTOIMMUNE DISEASES.

EHA Library, Sara Galimberti, 293565

PHENFORMIN INCREASES THE FREQUENCIES OF LSK, MULTIPOTENT PROGENITOR, AND MYELOID PROGENITOR IN JAK2V617F MURINE MODEL OF MYELOPROLIFERATIVE NEOPLASM

EHA Library, Antonio Bruno Alves-Silva, 293564

MOLECULAR CHARACTERISATION OF THE DER(6)T(1;6) IN MYELOID NEOPLASMS

EHA Library, Sophie Laird, 293563

FREQUENCY OF BCR-ABL1, JAK2V617F, MPLW515L/K AND CALR TYPE 1,2 MUTATIONS CO-OCCURENCE IN CML PATIENTS UNDERGOING TKI THERAPY AND ITS POSSIBLE PROGNOSTIC VALUE

EHA Library, Adhamjon Abdullaev, 293562

REWIRED CELL ENERGY METABOLISM IN A NOVEL KRAS-MUTATED HISTIOCYTOSIS CHARACTERIZED BY SEVERE SYNOVITIS

EHA Library, Giulio Cavalli, 293561

EXPRESSION OF CD47 AND CALR IN MYELOPROLIFERATIVE NEOPLASMS: POTENTIAL NEW THERAPEUTICAL TARGETS

EHA Library, Ciro Rinaldi, 293560

THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IS A CHEAP SURROGATE OF THE IMMUNESUPPRESSIVE MICROENVIRONMENT IN MYELOFIBROSIS AND MAY PREDICT RESPONSE TO RUXOLITINIB

EHA Library, Alessandra Romano, 293558

HOMOZYGOUS CALRETICULIN MUTATIONS AFFECT CHAPERONE FUNCTION AND PERTURB THE GLYCOPROTEOME

EHA Library, Patrick Schürch, 293557

NECROPTOTIC SIGNALING IS ENHANCED IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) FROM PATIENTS WITH MYELOFIBROSIS (MF)

EHA Library, Veronika Dill, 293556

NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES TO IDENTIFY POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME

EHA Library, Martina Barone, 293555

A NOVEL IN VITRO PLATFORM FOR THE PRIORITISATION AND VALIDATION OF INHIBITORS OF BONE MARROW FIBROSIS USING HUMAN BONE MARROW (BM) STROMAL CELLS

EHA Library, Michela Colombo, 293554

HLA CLASS I GENOTYPE SHAPES JAK2 V617F DRIVEN LEUKEMOGENESIS

EHA Library, Velizar Shivarov, 293553

IL-1RA LEVEL IN THE SERUM IS STRONGLY CORRELATED WITH THE JAK2V617F ALLELE BURDEN, MYELOFIBROSIS, SPLENOMEGALY AND SLAMF7HIGH CD16− MONOCYTES IN THE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Takaaki Maekawa, 293552

SETD2 PROTEIN LEVELS ARE A NOVEL PREDICTOR OF OVERALL SURVIVAL IN SYSTEMIC MASTOCYTOSIS

EHA Library, Michela Rondoni, 293550

CLONAL HETEROGENEITY AND EVOLUTION OF MPN REVEALED BY SINGLE-CELL RNA/DNA SEQUENCING

EHA Library, Xingxing Qi, 293549

IN SYSTEMIC MASOCYTOSIS, MIDOSTAURIN TARGETS BOTH KIT AND AURORA KINASE A REVERTING H3K36ME3 DEFICIENCY AND SYNERGIZES WITH NILOTINIB AND DASATINIB

EHA Library, Manuela Mancini, 293548

EXPLOITING THE CD47-SIRPΑ MACROPHAGE CHECKPOINT TO CONTROL POLYCYTHEMIA VERA

EHA Library, Veronika Lysenko, 293547

CLINICAL PHENOTYPES AND BLOOD FEATURES ASSOCIATED WITH CLONAL MYELOPOIESIS IN THE UK BIOBANK COHORT: ASXL1 MUTATIONS ARE STRONGLY ASSOCIATED WITH SMOKING HISTORY

EHA Library, Nick Cross, 293546

SURVIVAL TRENDS IN MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPIETIC STEM CELL TRANSPLANTATION

EHA Library, Samer Srour, 293545

AUTOLOGOUS STEM CELL TRANSPLANT AFTER INDUCTION THERAPY IMPROVES OUTCOME IN INITIALLY INELIGIBLE PATIENTS WITH SYSTEMIC IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS

EHA Library, Ilaria Cappuccio, 293544

GAIT SPEED AND HANDGRIP TEST TO ASSESS PHYSICAL FRAILTY IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Sotirios Bristogiannis, 293543

EFFECT OF PROLONGED TREATMENT WITH CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Cécile Gruchet, 293542

DOUBLE AND TRIPLE HIT MULTIPLE MYELOMA: NEW ULTRA HIGH-RISK ENTITIES?

EHA Library, Aleksandra Sretenovic, 293541

THE RELATIONSHIP BETWEEN NEGATIVITY OF SERUM FREE LIGHT CHAINS, MINIMAL RESIDUAL DISEASE, AND OVERALL SURVIVAL IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Kentaro Narita, 293540

A REAL-WORLD COMPARATIVE EFFECTIVENESS ANALYSIS OF PROTEASOME INHIBITOR-BASED REGIMENS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA UTILIZING A NATIONWIDE DATABASE IN JAPAN

EHA Library, Hirokazu Tanaka, 293539

POST-AUTHORIZATION SAFETY STUDY COMPARING LENALIDOMIDE-BASED TREATMENT VS NON−LENALIDOMIDE-BASED TREATMENT IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Barbara Gamberi, 293538

DREAMM-2 PIVOTAL STUDY: ANALYSIS OF THE LYOPHILIZED PRESENTATION COHORT OF SINGLE-AGENT BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, PAUL RICHARDSON, 293537

SPORADIC LATE ONSET NEMALINE MYOPATHY WITH MONOCLONAL PROTEIN IS A MALIGNANCY AND SHOULD BE TREATED WITH CHEMOTHERAPY-BASED APPROACH

EHA Library, Rouslan Kotchetkov, 293536

THE ORAL MICROBIOME IN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA TREATED WITH IXAZOMIB-THALIDOMIDE-DEXAMETHASONE (AGMT_MM-1 PHASE II TRIAL)

EHA Library, Heinz Ludwig, 293535

MULTIPLE MYELOMA FRAILTY POPULATION IN SPAIN: PRELIMINARY ANALYSIS OF THE INSIGHT MM REGISTRY

EHA Library, Noemi Puig, 293534

HEMATOLOGIC MALIGNACIES AND GAMMOPATHIES IN GAUCHER DISEASE TYPE 1

EHA Library, Maria Domenica Cappellini, 293533

SECOND PRIMARY MALIGNANCY IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 293586